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Abstract 
After a period where it was recommended to start antiretroviral therapy (ART) early, the CD4 threshold for treating 
asymptomatic adults dropped to 200/mm3 at the beginning of the 2000s. This was mostly due to a great prudence 
with regards to drug toxicity. The ART‑start CD4 threshold in most international guidelines was then raised to 350/
mm3 in 2006–2009 and to 500/mm3 in 2009–2013. Between 2012 and 2015, international guidelines went the last 
step further and recommended treating all HIV‑infected adults regardless of their CD4 count. This ultimate step was 
justified by the results of three randomized controlled trials, HPTN 052, Temprano ANRS 12136 and START. These three 
trials assessed the benefits and risks of starting ART immediately upon inclusion (“early ART”) versus deferring ART 
until the current starting criteria were met (“deferred ART”). Taken together, they recruited 8427 HIV‑infected adults 
in 37 countries. The primary outcome was severe morbidity, a composite outcome that included all‑cause deaths, 
AIDS diseases, and non‑AIDS cancers in the three trials. The trial results were mutually consistent and reinforcing. The 
overall risk of severe morbidity was significantly 44–57 % lower in patients randomized to early ART as compared to 
deferred ART. Early ART also decreased the risk of AIDS, tuberculosis, invasive bacterial diseases and Kaposi’s sarcoma 
considered separately. The incidence of severe morbidity was 3.2 and 3.5 times as high in HPTN052 and Temprano 
as in START, respectively. This difference is mostly due to the geographical context of morbidity. The evidence is now 
strong that initiating ART at high CD4 counts entails individual benefits worldwide, and that this is all the more true in 
low resource contexts where tuberculosis and other bacterial diseases are highly prevalent. These benefits in addition 
to population benefits consisting of preventing HIV transmission demonstrated in HPTN052, justify the recommenda‑
tion that HIV‑infected persons should initiate ART regardless of CD4 count. This recommendation faces many chal‑
lenges, including the fact that switching from “treat at 500 CD4/mm3” to “treat everyone” not only requires more tests 
and more drugs, but also more people to support patients and help them remain in care.
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Background
The optimal threshold for initiating ART: a 20‑year quest
1981–1996: The no‑treatment era
During the first 15 years of the HIV pandemic, no treat-
ment could sustainably control the replication of the 
virus and decrease mortality in HIV-infected people. The 
main direct and indirect consequence of the virus activity 
was infected and uninfected CD4 + T cells (CD4) death, 
causing progressively worsening immunosuppression, 
which exposed patients to the growing risk of oppor-
tunistic infection and death. The degree of immunosup-
pression and the subsequent risk of death over time were 
estimated with the CD4 count and with a clinical stage, 
as determined based on the opportunistic diseases that 
occurred in the patient. These two elements, CD4 count 
and clinical stage, enabled the setting of thresholds for 
some therapeutic decisions such as the initiation of 
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prophylaxis for the major opportunistic infections. This 
notion of “threshold” is crucial: it influenced the adminis-
tration of anti-HIV treatments for almost 30 years.
1996: The sudden arrival of a highly potent treatment
In the mi-1990s, the arrival of combined antiretroviral 
therapy (ART) revolutionizes the disease prognosis [1, 2]. 
This era is characterised by a combination of three fac-
tors: the evidence that combination therapy has a much 
more potent and durable effect than monotherapy, the 
introduction of protease inhibitors, and the capacity 
to measure plasma viral load using the new molecular 
amplification techniques. By controlling viral replication, 
combination ART prevents cell death, increases CD4 
count and restore immunity. This results in a dramatic 
decline in the risk of opportunistic infection and death 
[3]. In the first years of combination ART, “hit hard, hit 
early” becomes the mantra, with the hope that exerting 
maximal antiviral pressure on the virus during the ini-
tial phase of infection will prevent virus mutations and 
favour treatment success [4].
Combination ART controls the virus, however, it does 
not eradicate it. HIV reservoirs are shown to persist, even 
if plasma viremia is successfully suppressed for prolonged 
periods of time [5, 6]. From a fatal untreatable disease, 
HIV infection thus becomes a chronic disease requir-
ing lifelong treatment. Like any chronic therapy, ART 
involves adherence issues and carries risks of cumulative 
toxicity; and like any anti-infective therapy, it carries risks 
of emergence of resistance, especially if it is not taken 
properly. To spare the patient unnecessary risks of toxic-
ity and resistance, ART should therefore not be initiated 
“too early”—i.e. at an immuno-clinical stage where the 
treatment risks would outweigh the disease risks. This is 
where the quest for the “optimal immuno-clinical thresh-
old for initiating ART” begins.
1996–2014: Looking for the golden CD4 threshold
“When to start ART?” is essentially a risk/benefit ques-
tion, but knowledge on benefits and risks changes over 
time. During the first 10  years of ART, the ART-start 
threshold fluctuates. After a short period in the late 
1990s where it is recommended to start treatment from 
500 CD4/mm3 without randomized trial evidence, 
threshold for treating asymptomatic adults drops to 200/
mm3 at the beginning of the 2000s (Fig. 1) [7]. This shift 
is mostly due to a great prudence with regards to drug 
toxicity, especially cardiovascular or cerebrovascular, 
metabolic and renal. This is the time when, in order to 
spare toxicity, researchers carry out randomized trials of 
structured treatment interruption (STI), in which ART-
treated patients whose CD4 count rises above 350/mm3 
are proposed to temporarily interrupt their treatment [8, 
9]. The underlying assumptions are that ART is the main 
determinant of all the non-HIV adverse effects and ill-
ness being observed in the early era of combination ART, 
Fig. 1 Temporal evolution of CD4 criteria to initiate ART in asymptomatic HIV+ adults (IAS, DHHS, EACS and WHO Guidelines)(1). (1) Adapted from 
Marco Antonio Vitoria, WHO, Geneva. cART combined antiretroviral therapy. DHHS U.S. Department of Health and Human Services. EACS European 
AIDS Clinical Society. IAS International AIDS Society. WHO World Health Organisation
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and that ART’s primary goal is to maintain CD4 above 
200/mm3. Therefore, any drug exposure beyond this tar-
get potentially entails unnecessary side effects.
In 2006, the results of the STI trials annihilate this 
approach. Contrary to the pre-trial hypotheses, the 
Trivacan and SMART trials show that patients who tem-
porarily interrupt ART at the threshold of 350 CD4/mm3 
have higher risk of severe morbidity compared to those 
who do not interrupt ART at the same threshold [8, 9]. 
In other words, below 350/mm3, HIV disease itself is 
more toxic than antiretroviral drugs. Furthermore, STI 
trial results no only suggest that people should worry 
more about starting ART earlier than about interrupting 
it. They shed important light on HIV morbidity, make us 
focus back on the virus, and illustrate the importance of 
the context.
In STI trials conducted in high resource countries, a 
significant part of the extra morbidity related to treat-
ment interruptions is made up of non-infectious dis-
eases—non-AIDS cancers, cardiovascular and renal 
diseases, and interruptions leads to a rise in inflamma-
tion markers [10, 11]. After more than 20 years of focus-
ing on AIDS-defining opportunistic diseases (mostly 
infectious) at low CD4 counts, the focus thus becomes on 
non-AIDS HIV-related diseases (mostly non-infectious) 
at high CD4 counts. Part of these diseases being likely 
due to viral replication, rather than to immune suppres-
sion, the question is not whether the ART-start threshold 
will continue to rise anymore, but how high it will get.
In STI trials conducted in low resource countries, 
however, most of the extra morbidity related to treat-
ment interruptions is made up of tuberculosis and inva-
sive bacterial diseases [8, 12]. These infectious diseases 
are more frequent in poor settings than in rich settings. 
They are community diseases, but also act as oppor-
tunistic diseases, meaning that they are more frequent 
in HIV-infected individuals than in HIV-non infected 
ones. Thus, it is not that surprising that the overall risk 
of severe morbidity in HIV-infected patients at any CD4 
count is higher in low resource settings as compared to 
high resource ones. Therefore, at the end of the 2000s, 
if the case for raising the ART-start threshold is already 
strong worldwide because of HIV non-AIDS non-infec-
tious diseases, it is even stronger in regions where tuber-
culosis and bacterial diseases are more prevalent.
From there onwards the trend toward earlier initiation 
of ART is unstoppable. Two multicohort studies from 
industrialized countries suggest that 350/mm3 should 
be the minimum threshold for initiation of antiretroviral 
therapy [13, 14]. A randomized trial carried out in Haiti 
demonstrates that starting ART immediately in patients 
enrolled with less than 350 CD4/mm3 decreases the rates 
of death and incident tuberculosis compared to starting 
ART at 200 CD4/mm3 [15]. Between 2006 and 2009 the 
ART-start threshold is raised to 350/mm3 worldwide. 
Between 2009 and 2013, most guidelines further set the 
threshold to 500/mm3, the shift being quicker—with 
some exceptions—in high resource countries than in low 
resource ones. Raising the CD4 threshold to 500/mm3 is 
based on high-quality evidence from HPTN052 that ART 
reduces HIV transmission, but low-quality evidence from 
cohort studies that ART reduces mortality or progression 
to AIDS [16].
Finally, between 2012 and 2015, all international guide-
lines take the last step and recommend treating all HIV-
infected adults regardless of their CD4 count [17–20]. 
This ultimate step is either corroborated or directly 
inspired by the results of three randomized controlled 
trials, HPTN 052, Temprano ANRS 12136 and START 
[21–24].
HPTN 052, Temprano ANRS 12136 and START: the three 
early ART trials
HPTN 052, Temprano and START were three open label 
randomized controlled trials. They took place between 
2007 and 2015. Taken together, they recruited a total 
8427 HIV-infected adults in 37 countries, including 48 % 
in Africa, 37 % in Europe, US, Australia or Israel, 17 % in 
Latin America, and 10 % in Asia (Table 1; Fig. 2).
The three trials had the same primary objective, that is 
to assess the benefits and risks of starting ART immedi-
ately upon inclusion (“early ART”) versus deferring ART 
initiation until the current institutional starting criteria 
were met (“deferred ART”). The primary outcome was 
severe morbidity, a composite outcome that included all-
cause deaths, AIDS diseases, and non-AIDS cancers in 
the three trials. In addition to these three components, 
the primary outcome also included: severe bacterial dis-
eases in Temprano and HPTN052; serious cardiovascular 
diseases in START and HPTN052; diabetes mellitus in 
HPTN052; and renal or liver failure in START. HPTN052 
had a co-primary endpoint, HIV transmission to the 
partner, and was primarily powered to interrogate HIV 
transmission.
Asymptomatic patients were eligible for the trial if they 
had CD4 counts between 350 and 550/mm3 in HPTN052, 
between 250 and 800/mm3 in Temprano, and higher than 
500/mm3 in START. As a consequence, the median CD4 
count at baseline was 436/mm3 in HPTN052, 463/mm3 
in Temprano and 651/mm3 in START, and the highest 
CD4 count at baseline was 550/mm3 in HPTN052, 1456/
mm3 in Temprano and 2296/mm3 in START. In Tem-
prano, 41 % of participants had more than 500 CD4/mm3 
at baseline.
During the trial, asymptomatic patients randomized 
into the deferred ART strategy started ART at 250/mm3 
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in HPTN052 and 350/mm3 in START. In Temprano, 
the ART-start threshold was adjusted upward over time 
according to WHO guidelines updates, from 200/mm3 
in 2008–2009 to 350/mm3 in 2009–2013 and 500/mm3 
in 2013–2015. The median follow-up in the trials varied 
from 2.1 to 2.8 years.
Fig. 2 Geographical location of HPTN052, Temprano and START. Source Adapted from a Wikipedia map from http://www.vectorworldmap.com/; 
public domain. Asterisks recruitment for the START trial in Europe: Germany 7 %, United Kingdom 7 %, Spain 5 %, Belgium 2 %, France 2 %, Greece 
2 %, Denmark 1 %, Italy 1 %, Poland 1 %, Portugal 1 %, Switzerland 1 %, others (Czech republic, Estonia, Finland, Luxemburg, Norway, Sweden, 
Ireland, all <1 %)
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The three trials had notable differences in terms of 
prevention and documentation of tuberculosis. Firstly, 
Temprano was a factorial 2 ×  2 trial assessing in paral-
lel two questions: early ART, and early INH preventive 
therapy (IPT). Therefore, participants were randomized 
not only to early or deferred ART, but also to start or 
not a 6-month course of IPT after 1 month of follow-up, 
provided they had no signs or symptoms evocative of 
tuberculosis. As a consequence, 45  % of participants in 
Temprano received IPT, versus only 3 % in HPTN052 and 
an unknown number in START. Secondly, in Temprano 
and HPTN052 all cases of confirmed and probable tuber-
culosis were documented and included in the primary 
outcome, while in START only confirmed cases with pos-
itive cultures were retained. The main results of the three 
trials were mutually consistent and reinforcing in terms 
of relative risks, while showing geographical context-spe-
cific absolute risks (Table 2).
In terms of absolute risks, the incidence of severe mor-
bidity in the deferred ART strategy was 3.2 and 3.5 as 
high in HPTN052 and Temprano compared to START, 
respectively. This difference is likely explained by the con-
text (more patients in low resource settings in HPTN052 
and Temprano), the population (higher baseline CD4 
count in SMART), and the differences in the documenta-
tion of tuberculosis discussed above.
In terms of relative risks, the overall risk of severe mor-
bidity was 44–57 % lower in patients randomized to the 
early ART strategy as compared to those randomized 
to the deferred ART strategy in Temprano and START, 
respectively. In Temprano, the reduction in severe mor-
bidity was of similar magnitude and remained significant 
when restricting the analysis to patients who had more 
than 500 CD4/mm3 at baseline. In HPTN052, the overall 
difference did not reach significance.
When considering separately each component of the 
composite primary outcome or important secondary 
outcomes, early ART significantly decreased the risk of: 
AIDS in the three trials; tuberculosis considered sepa-
rately in the three trials; invasive bacterial diseases in 
Temprano and SMART; and Kaposi’s sarcoma in SMART. 
These are secondary analysis whose power may be lim-
ited by the number of events in each group. As shown in 
Table  2, the number of AIDS or non-AIDS HIV-related 
events was lower with early ART than in deferred ART 
in almost every subgroup, even if this difference did not 
always reach significance. Of note, in Temprano, the trial 
who assessed in parallel the efficacy of early ART and 
IPT, IPT also reduced the risk tuberculosis by 66 % over-
all, 68 % in patients who had less than 500 CD4/mm3 at 
baseline and 63 % in those who had more than 500 CD4/
mm3 at baseline. The efficacy of ART and IPT in reducing 
tuberculosis was independent [22].
Finally, in the three trials, ART appeared to be equally 
well tolerated in both strategies (data not shown).
Discussion
These three trials were conducted in different geographi-
cal contexts and in populations at various immunosup-
pression stages. This diversity strengthens their common 
conclusion: all over the world, HIV-infected persons 
should be recommended to initiate ART regardless of 
CD4 count. ART initiation should not be triggered by any 
clinical or immunological threshold anymore, and the 
objective of ART clearly becomes to suppress viral repli-
cation and prevent—rather than cure—inflammation and 
immune deficiency.
Broadening treatment eligibility directly leads to 
increase the number of individuals treated. Switch-
ing from treating at 500 CD4/mm3 to treating all HIV-
infected persons irrespective of CD4 count meets many 
barriers and challenges, especially in low resource set-
tings. Of the 35 million people living with HIV, about 19 
million do not even know that they are HIV-positive [25]. 
The majority of those who know their status still present 
to care late with low CD4 counts [26]. We need a robust 
testing agenda, including innovative approaches such 
as community-based testing and self-testing to encour-
age early testing [27]. Furthermore, testing and initiat-
ing treatment early is not worth spending energy on it if 
patients stop treatment afterwards. Therefore, initiating 
ART irrespective of CD4 count in settings with high HIV 
burden requires increased capacity not only in terms 
of tests and drugs, but also in terms of infrastructures 
and trained staff empowered to support patients [28]. 
In resource-constrained settings, a phased approach to 
implementation may be needed [29, 30].
Finally, the randomized trials have shown that the 
benefits/risk ratio of starting ART irrespective of CD4 
count is favorable. However, if ART at any CD4 count 
is proven to have strong benefits globally, the question 
remains open of whether these benefits may outweigh 
the risks in subgroups of patients, such as HIV control-
lers [31]. Therefore, now that we have given a global 
answer to the question of ‘when to start ART’, we should 
explore to question of ‘when not to start ART immedi-
ately’ at the individual level [16]. Should these challenges 
be addressed, recommending initiating ART irrespec-
tive of CD4 count may bring benefits that extend beyond 
the individual benefits demonstrated in HPTN 052, 
Temprano and START. A person who starts treatment 
earlier is less exposed to the initial complications of the 
treatment such as immune constitution inflammatory 
syndrome (IRIS), and thus easier to manage. In addi-
tion, not having to wait for a CD4 count result to decide 
whether to initiate ART should facilitate and shorten 
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the pre-treatment period. These two advantages should 
accelerate task delegation and help decentralize care, 
thus increasing the likelihood that the UNAIDS target of 
90 % of all people with diagnosed HIV infection receiv-
ing sustained ART will be reached by 2020 [32] . In addi-
tion, ART does not just reduce morbidity in the treated 
individuals, it also reduces the number of people with a 
detectable viral load. It thus contributes to reducing HIV 
transmission and to controlling the HIV epidemic [24]. 
Finally, in the many countries where HIV and tubercu-
losis are both highly prevalent, ART and IPT indepen-
dently decrease the risk of tuberculosis in HIV-infected 
patients, even at high CD4 counts. Therefore, initiating 
ART early should help decrease the risk of tuberculosis 
Table 2 Main outcomes of the three early ART randomized controlled trials (HPTN052, Temprano ANRS 12136, START)
N number of participants who had at least one such type of outcome; ART antiretroviral treatment; NA non available; PY person-years
a Component of the composite primary outcome in the three trials
b Total number of pulmonary and extra pulmonary TB episodes recorded in the three trials: HPTN052: pulmonary, n = 30 (early: 14; deferred: 16); extra-pulmonary, 
n = 20 (early: 3; deferred: 17); Temprano ANRS 12136: pulmonary, n = 43 (early: 19; deferred: 24); extra-pulmonary, n = 41 (early: 9; deferred: 33). START: pulmonary, 
n = 23 (early: 6; deferred: 17); extra-pulmonary, n = 3 (early: 0; deferred: 3)
c Cervical carcinoma, Kaposi’s sarcoma, Lymphoma, Hodgkin’s, Lymphoma, non-Hodgkin’s non-AIDS cancers
d Invasive bacterial diseases were a component of the composite primary outcome in Temprano and HPTN052, and a secondary outcome in START
e Serious cardiovascular diseases were a component of the composite primary outcome in START and HPTN052, and a secondary outcome in Temprano
f The trials analyses were adjusted for geographic regions (START) or study site (HPTN 052 and Temprano). In Temprano, Hazard Ratios were also adjusted for the IPT/
no IPT treatment
Deferred ART Early ART Adjusted hazard 
ratiof (95 % CI)
N Rate per 100 PY N Rate per 100 PY
Composite primary outcome
 HPTN052 91 4.5 71 3.5 0.73 (0.52–1.03)
 Temprano 111 4.9 64 2.8 0.56 (0.41–0.76)
  Baseline CD4 < 500 73 5.5 41 3.0 0.56 (0.38–0.83)
  Baseline CD4 ≥ 500 38 4.1 23 2.4 0.56 (0.33–0.94)
 START 96 1.4 42 0.6 0.43 (0.30–0.62)
Separated outcome
 Deatha
  HPTN052 15 NA 11 NA 0.73 (0.34–1.59)
  Temprano 26 1.9 21 0.8 0.80 (0.45–1.40)
  START 21 0.3 12 0.2 0.58 (0.28–1.17)
 AIDSa
  HPTN052 61 NA 40 NA 0.64 (0.43–0.96)
  Temprano 65 2.8 33 1.4 0.50 (0.33–0.76)
  START 50 0.7 14 0.2 0.28 (0.15–0.50)
 Tuberculosisa,b
  HPTN052 34 1.8 17 0.8 0.49 (0.28–0.89)
  Temprano 55 2.4 28 1.2 0.50 (0.32–0.79)
  START 20 0.3 6 0.1 0.29 (0.12–0.73)
 AIDS and non‑AIDS malignanciesa,c
  HPTN052 7 NA 4 NA NA
  Temprano 6 NA 3 NA NA
  START 39 NA 14 NA NA
 Invasive bacterial diseasesd
  HPTN052 13 NA 20 NA NA
  Temprano 36 1.5 14 0.6 0.39 (0.21–0.71)
  START 36 0.5 14 0.2 0.38 (0.20–0.70)
 Serious cardiovasculare
  HPTN052 3 NA 1 NA NA
  Temprano 6 NA 3 NA NA
  START 14 0.20 12 0.17 0.84 (0.39–1.81)
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transmission and further contribute to tuberculosis con-
trol [33] and IPT should be given even to patients who 
start ART at high CD4 counts [22].
Conclusions
In conclusion, the evidence is now strong that initiat-
ing ART at high CD4 counts entails individual benefits, 
and that this is all the more true for those who live in low 
resource contexts. These individual benefits in addition 
to previously demonstrated population benefits, consist-
ing of preventing HIV transmission to non-HIV-infected 
partners, fully justify the universal recommendation that 
HIV-infected persons should be recommended to initi-
ate ART regardless of CD4 count. This recommendation 
faces many challenges, including the fact that switch-
ing from “treat at 500 CD4/mm3” to “treat everyone” is 
not only a matter of more tests and more drugs. It also 
requires more people to support patients and help them 
remain in care once they started treatment. Over the past 
years, the “Test and Treat” model has evolved to “Seek, 
Test, Treat and Retain”. Until HIV can be eradicated, it 
should now be formulated this way: “Seek, test and treat 
every HIV infected persons, and empower staff and 
patients to ensure lifelong treatment continuity” [28].
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